Question · asked by 1 review

Summary of findings: aztreonam lysine for inhalation vs tobramycin: Need for antibiotics see pulmonary exacerbations

Summary of findings: aztreonam lysine for inhalation probably leads to lower pulmonary exacerbations: need for additional antibiotics compared with tobramycin (moderate certainty).

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
Summary of findings: aztreonam lysine for inhalation vs tobramycin
Pulmonary exacerbations: need for additional antibiotics · children and adults with CF and P aeruginosa
Summary of findings: aztreonam lysine for inhalation probably leads to lower pulmonary exacerbations: need for additional antibiotics compared with tobramycin (moderate certainty).
Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane Headline outcomes only
RR 0.66 [0.51, 0.86]1 study · 268 participantsModerate
Summary of findings: aztreonam lysine for inhalation vs tobramycin
Pulmonary exacerbations: need for additional antibiotics. · children and adults with CF and P aeruginosa
Summary of findings: aztreonam lysine for inhalation probably leads to lower pulmonary exacerbations: need for additional antibiotics. compared with tobramycin (moderate certainty).
Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2018) · Cochrane Headline outcomes onlyearlier version CD001021.PUB3, superseded
RR 0.66 [0.51, 0.86]1 study · 268 participantsModerate

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis
2022 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.